Micreos Information

MICREOS is a Swiss-based biotechnology company pioneering a new class of precision biologics—engineered endolysins designed to selectively eliminate disease-driving pathogens while preserving healthy microbial ecosystems. Built on more than 15 years of endolysin research and a long-standing collaboration with ETH Zürich, MICREOS combines expertise in microbiology, protein engineering, and therapeutic development to advance innovative treatments for pathogen-driven diseases. Our lead candidate, MEndoB, is an engineered endolysin designed to selectively eliminate Staphylococcus aureus, a key contributor to inflammation and disease severity in atopic dermatitis. Beyond dermatology, our platform holds potential across a broad range of indications, including wound infections, cutaneous T-cell lymphoma, and serious bacterial infections. Our vision: A future where harmful pathogens can be precisely eliminated while preserving the healthy biology that protects us.